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ABEL E. MOREYRA, MD, FACC, JOHN B. KOSTIS, MD, FACC 
New Brunswick, New Jersey 
The coronary dilative and systemic responses to graded 
doses of intracoronary nitroglycerin were studied in 53 
patients undergoing diagnostic coronary arteriography, 43 
of whom had received a cutaneous nitroglycerin patch. 
During coronary arteriography, graded doses of 50, 100 
and 200 pg of intracoronary nitroglycerin were given 5 min 
apart. An arteriogram and hemodynamic measurements 
were obtained after each dose. In the control group (n = 10) 
cumulative intracoronary nitroglycerin doses of 50,150 and 
350 pg caused a? increase in coronary diameter in the left 
anterior descending artery of 20 f 4%, 21 2 3% and 22 + 
7 %, respectively, and in the circumflex artery of 18 f 6%) 
23 + 8% and 18 -C 5% (p < 0.01 versus values in untreated 
group). 
In Group 1 (15 patients given a 5 mg/24 h nitroglycerin 
patch 2 to 12 h before coronary arteriography), the same 
intracoronary nitroglyqrin doses increased the left ante- 
rior descending artery diameter by 6 f 2%, 7 +. 2% and 7 
f 2%) respectively, and the circumflex artery diameter by 
3 f 2%, 3 + 2% and 1 + 3%. All values were statistically 
The use of nitroglycerin patches has aroused both interest 
and controversy. The introduction of transdermal patches 
with release of nitroglycerin at a constant rate for 224 h was 
greeted with enthusiasm, but investigators have since ques- 
tioned their efficacy. The possibility of early nitrate toler- 
ance or “attenuation” of their effects has been raised and 
therefore the clinical usefulness of these patches has come 
under question (l-6). 
Measurements of coronary artery diameter are useful for 
quantitating coronary responses to interventions (7). Inves- 
From the Departments of Medicine and Pharmacology, University of 
Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School 
and University Hospital, New Brunswick, New Jersey. 
Manuscript received March 28. 1988; revised manuscript received August 
8, 1988, accepted September 5, 1988. 
Address for reorints: Abel E. Moreyra. MD, Division of Cardiovascular 
Diseases and Hypertension, Department of Medicine, University of Medicine 
and Dentistry of New Jersey-Robert Wood Johnson Medical School, One 
Robert Wood Johnson Place, CN 19. New Brunswick, New Jersey 08903-0019. 
different from control (p < 0.05). An even more pro- 
nounced blunting (p < 0.01) of the coronary dilative 
response was observed in Group 2 (14 patients given a 15 
mg/24 h nitroglycerin patch 2 to 12 h before arteriography). 
The diameter responses to intracoronary nitroglycerin ob- 
served in Group 3 (seven patients given a 5 mg/24 h 
nitroglycerin patch 24 h before ayteriography) and Group 4 
(seven patients given a 15 mg/24 h nitrogljicerin patch 24 h 
before arteriography) were not significantly different from 
those of the control group. 
The results demonstrate that a nitroglycerin patch ad- 
ministereg a few hours before coronary arteriography 
caused significant coronary artery dilation and that the 
incremental dilation due to the intracoronary nitroglycerin 
was small. On the other hand, 24 h after arteriography, the 
coronary dilative effect of the patch was attenuated (sug 
gesting development of tolerance) and the increment in 
diameter induced by intracoronary nitroglycerin was much 
larger. 
(J Am Co11 Cardiol1989;13:428-33) 
tigations (8,9) have shown a dose-response relation between 
coronary artery dilation and the dose of nitroglycerin admin- 
istered. In this investigation we studied the degree of coro- 
nary artery dilation resulting from increasing doses of intra- 
coronary nitroglycerin in patients who had received a 
nitroglycerip patch (Nitro-Dur, Key Pharmaceutical) 2 tq 24 
h before coronary arteriography. 
Methods 
Patient selection. Fifty-three patients undergoing cardiac 
catheterization for evaluation of chest pain were studied 
after giving informed consent. Patients with acute myocar- 
dial infarction, unstable angina or symptoms suggesting 
variant angina were excluded. 
Cardiac catheterization. Left heart catheterization and 
coronary arteriography were performed with the Judkins 
technique. All coronary vasodilators were withheld 48 h 
before catheterization. The patients were in a postabsorptive 
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Table 1. Patient Characteristics 
Age (yr) 
Coronary Artery Disease 
(mean + SD: 
(>50% diameter stenosis) 
No. M/F range) Normal IV ?V ?V 
Control group IO 713 51.1 + 7.9: 4 I 3 2 
35 to 60 
Group I 15 916 55.1 i 10.3; 4 4 5 2 
38 to 70 
Group 2 14 91.5 58.6 i 11.3: 4 3 2 5 
38 to 74 
Group 3 7 314 53.6 ? 8.7: I 1 4 - 
39 to 65 
Group 4 7 611 62.4 + I I .7: 2 2 ? I 
42 to 75 
F = female; M = male: V = vessel. 
state with mild sedation (diazepam, 10 mg intermuscularly) 
when catheterized. Ten patients who did not receive a 
nitroglycerin patch served as the control group. Fifteen 
patients received a 5 mg/24 h nitroglycerin patch (Group I) 
and 14 patients a I.5 mg/24 h patch (Group 2) 2 to I2 h before 
coronary arteriography (median for Group 1, 6 h and for 
Group 2, 7 h). In addition, seven patients received a 5 mg/24 
h nitroglycerin patch (Group 3) and seven patients a 15 mgi 
24 h (Group 4) 24 h before the procedure. 
Multiple views of the left coronary artery were obtained 
with use of an appropriate /eft Judkins catheter. The right 
anterior oblique view (10 to 30”) was chosen to optimize 
visualization of both left anterior descending and circumflex 
systems. Renografin-76, 6 to 8 ml per angiogram injected 
manually, was used as contrast medium. The filming rate 
was 30 frames/s with 12.5 cm image intensification and I.2 
mm focal spot. After the control angiogram and hemody- 
namic measurements (systolic, diastolic and mean aortic 
pressures and heart rate) were obtained, graded doses of 50 
pg, 100 pg (cumulative dose 150 pg) and 200 pg (total 
cumulative dose 350 pg) of intracoronary nitroglycerin were 
given 5 min apart. An arteriogram and hemodynamic mea- 
surements were obtained 3 min after each dose. The pa- 
tient’s position was maintained constant throughout the 
study. In addition, the relation between the focal spot, 
patient and height of the image tube was kept constant. At 
each dose, cineangiographic frames obtained at end of 
diastole were analyzed. Midcoronary segments free of dis- 
ease were selected for the measurement. To ensure that the 
same segments were examined with each dose, coronary 
branch points were used as reference points. To assess the 
effect of contrast material on coronary artery diameter, five 
additional patients had four successive coronary arterio- 
grams with the omission of nitroglycerin. Measurements of 
coronary diameters in these angiograms showed either min- 
imal (~5%) or no detectable changes. 
Measurements of coronary artery diameter. The selected 
angiographic frames were enlarged to 203 x 254 mm hard 
copies and coded for analysis in a blinded fashion. Measure- 
ments of the coronary artery diameter were made by a single 
observer using an electronic caliper (DEC, Prodical 1101, 
Accurex). The precision and accuracy of this measuring 
technique for stenosis assessment has been well described 
(IO). The intra- and interobserver variability of the tech- 
niques in measuring the diameter of normal coronary seg- 
ments was tested in seven patients by four observers un- 
aware of other patient data. The intraobserver variability 
was tested by repeated (IO) diameter measurements of a 
normal coronary segment. The coefficient of variation for 
intra- and interobserver variability ranged from I .4 to 4.3%. 
In addition, to assure an unbiased measurement of arterial 
diameter. observers had no knowledge of the sequence, 
control or treatment group or nitroglycerin dose. Actual 
coronary artery diameter (in millimeters) was calculated by 
reference to the catheter tip (1.81 mm). Percent increases in 
diameter from baseline were calculated for each subject and 
averaged to provide the mean increase in arterial diameter. 
Statistical analysis. Changes in coronary artery diameter, 
mean arterial pressure and heart rate were grouped for each 
patient according to intracoronary nitroglycerin dose. Mean 
values and SEM were calculated. Data were analyzed by 
analysis of variance (repeated measures design) with use of 
the SAS general linear models procedure (SAS Statistics 
Guide for Personal Computers, SAS Institute). Arterial 
diameters in each group at baseline were compared by 
one-way analysis of variance. Duncan’s multiple range test 
was used to identify significant differences between levels of 
the independent variable. 
Results 
Patient data (Table 1). The study group consisted of 53 
patients. Fifteen patients had normal coronary arteries and 
38 patients had coronary artery disease as defined by ~50% 
stenosis in one or more vessels. Only angiographically 
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Table 2. Effect of 50, 100 and 200 pg Intracoronary Nitroglycerin on Diameter (mm) of Midsegments of Left Anterior Descending and 
Circumflex Arteries (mean ? SD) 
Groups Baseline 
Left Anterior Descending Artery 
50 clg 100 pg 
Left Circumflex Artery 
200 peg Baseline 50 clg 100 pg 200 /Jg 
No patch: control 
(n = IO) 
5 mg/24 h patch 2 to 
12 h before art.: 
Group I (n = IS) 
15 mg/24 h patch 2 to 
12 h before art.: 
Group 2 (n = 14) 
5 mgi24 h patch 24 h 
before art.: Group 3 
(n = 7) 
15 mgi24 h patch 24 h 
before art.: Group 4 
(n = 7) 
* 
2.08 t 0.51 2.46 ? 0.42 
t 
2.26 ? 0.45 2.37 2 0.43 
* 
2.49 ? 0.54 
* 
2.56 ” 0.72 
t 
2.39 2 0.45 
* 
2.11 2 0.53 2.45 + 0.53 
NS 
2.70 2 0.61 2.80 k 0.68 
* 
2.53 * 0.52 
NS 
2.78 + 0.68 
* 
2.51 * 0.55 
NS 
2.76 + 0.62 2.40 r 0.44 
NS 
2.69 ” 0.31 
t NS 
3.05 ? 0.64 3.24 + 0.37 
NS 
3.05 k 0.51 
NS 
3.14 * 0.51 
$ NS 
2.69 * 0.38 2.65 + 0.34 
NS 
2.78 + 0.33 
* 
2.02 + 0.58 2.29 k 0.56 
* 
2.39 + 0.55 
* 
2.45 ? 0.48 
t 
2.44 ? 0.87 2.72 ? 0.82 
t 
2.79 ? 0.75 
t 
2.78 + 0.74 
* 
2.42 t 0.42 2.66 2 0.32 
* 
2.73 + 0.34 
* 
2.75 ? 0.40 
t 
2.69 ? 0.32 2.93 ? 0.55 
t 
2.99 ? 0.44 
t 
3.00 + 0.63 
* = p < 0.01 from baseline; t = p < 0.05 from baseline; art. = coronary arteriography; $ = different (p < 0.05) from baseline diameter in corresponding control 
group; NS = no significant difference from baseline. 
normal segments of vessels were examined. Patient charac- 
teristics in each group are described in Table 1. 
Effect of intracoronary nitroglycerin in diameter of mid- 
segments of left anterior descending and circumflex arteries 
(Table 2). In the control group, increasing doses of intraco- 
ronary nitroglycerin (50, 100 and 200 pg) evoked an impor- 
tant increase in diameter in both left anterior descending and 
circumflex coronary arteries. This type of response was not 
observed in Groups 1 and 2, except for left anterior descend- 
ing artery segments in Group 1. It should be noted that the 
percent changes of these segments (left anterior descending 
artery, Group 1) were significantly smaller from those in the 
control group (Fig. 1). A significant increase in coronary 
artery segment diameter was again observed in Groups 3 and 
4. Baseline diameters for the left anterior descending and 
circumflex arteries in the treatment groups were not statis- 
tically different from those in the control group except in 
Group 2. 
Dilation of coronary artery midsegments after cumulative 
doses of intracoronary nitrogiycerin. Control group. Diame- 
ter responses of the left anterior descending and circumflex 
arteries to intracoionary nitroglycerin are shown in Figure 1. 
At a dose of 50 pg, left anterior descending artery diameter 
increased by 20 t 4% and circumflex coronary artery 
diameter increased by 18 ? 6%. At a dose of 100 pg (150 & 
cumulative), left anterior descending artery diameter in- 
creased by 21 ? 3% and circumflex artery diameter by 23 ? 
8%. At a dose of 200 pg (350 pg cumulative), left anterior 
descending artery diameter increased by 22 2 7% and 
circumflex artery diameter by 18 2 5%. All values were 
significantly different (p < 0.01 from the untreated values). 
Coronary artery dilation in patients who received 5 mgl24 
h patch (Group I) and 15 mgl24 h patch (Group 2), 2 to 12 h 
before coronary arteriography (Fig. 1). Intracoronary nitro- 
glycerin doses of 50, 100 and 200 pg in the left coronary 
artery in Group 1 patients, who had received a 5 mg/24 h 
nitroglycerin patch, caused an increase in diameter of the left 
anterior descending artery of 6 + 2%, 7 + 2% and 7 + 2%, 
respectively, and in the circumflex artery of 3 + 2%, 3 ? 2% 
and 1 ? 3%, respectively. For Group 2 patients, who had 
received a 15 mg/24 h nitroglycerin patch, the changes 
induced by the same intracoronary nitroglycerin doses in 
coronary diameter were -2 ? 3%, 4 ? 1% and 0 ? 2%, 
respectively, for the left anterior descending artery and 3 ‘_ 
Figure 1. Effect of graded doses of intracoronary nitroglycerin 
(NTG) (SO, 100, 200 pg) on coronary artery dilation in patients who 
had received a nitroglycerin patch 2 to 12 h before coronary 
arteriography. * = p < 0.05; ** = p < 0.01 compared with values in 
control group (no patch); LAD = left anterior descending artery; 
LCx = left circumflex artery. 
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Figure 2. Effect of graded doses of intracoronary (50. 100, 200 ~g) 
nitroglycerin (IC-NTG) on coronary artery diameter in patients who 
had received a nitroglycerin patch 24 h before coronary arteriogra- 
phy. The mean increase in arterial diameter was not statistically 
different from values in the control group (no patch). Abbreviations 
as in Figure I. 
5%, 1 ? 4% and 2 2 4%, respectively, for the circumflex 
artery. The blunting of the coronary dilator response to 
intracoronary nitroglycerin was statistically significant for all 
doses in both arteries. 
Coronclry artery dilation in patients who received 5 mgi24 
h (Group 3) and 15 mgl24 h (Group 4) 24 h before coronary 
arteriography (Fig. 2). The response to intracoronary nitro- 
glycerin in Group 3 patients, who received a small dose 
patch (5 mg/24 h), was not significantly different from that of 
the control group; in the left anterior descending artery the 
dilation was 15 k 7% for the 50 pg dose, 21 k 7% for the 100 
pg dose and 25 i 7% for the 200 pg dose. The corresponding 
increases in the circumflex artery diameter were 12 k 3%, 19 
+ 7% and 20 f. 8%, respectively. 
In the Group 4 patients, who received a large dose patch 
(15 mg/24 h), the dilative response to the same grade doses of 
intracoronary nitroglycerin (50, 100 to 200 pg) for the left 
anterior descending artery was 11 rt 4%, I3 2 3% and 
14.3%, respectively, and for the circumflex artery 8 + 4%, 11 
+ 3% and I I ? 6%, respectively. Although a trend toward a 
“blunting” of the dilative response of the coronary arteries 
was observed, these responses in arterial diameter were not 
statistically different from those of the control group. 
Effect of cumulative doses of intracoronary nitroglycerin on 
heart rate and aortic pressure (Table 3). In the control group, 
as well as in the study groups, there was a gradual decrease 
in mean arterial blood pressure. At the highest cumulative 
dose of 350 pg of intracoronary nitroglycerin, mean blood 
pressure decreased in the control group by I1 f 5 mm Hg, in 
Group I by I2 2 9 2 mm Hg, in Group 2 by 7 2 5 mm Hg, 
in Group 3 by 15 2 6 mm Hg, and in Group 4 by 8 k 5 mm 
Hg. Differences between the control and study groups at 
each intracoronary nitroglycerin dose level were not statis- 
tically significant at the 0.05 level. 
There was a small (- 1 2 6 beats) change in heart rate in 
the control group at the maximal cumulative nitroglycerin 
dose. Similarly, in different study groups, there were only 
small changes in heart rate (Group I, 5 ? 8 beats; Group 2, 
1 2 4 beats; Group 3, 6 + 8 beats; Group 4. 0 + 7 beats. 
Differences in heart rate between the control and study 
groups at each intracoronary nitroglycerin dose level were 
not statistically significant. 
Discussion 
Tolerance to organic nitrates. There is still controversy 
about the occurrence and characteristics of tolerance to 
organic nitrates in patients with coronary artery disease (1 I- 
13). In patients with congestive heart failure, tolerance has 
been demonstrated several times by continued hemody- 
namic monitoring (14-16). In patients with angina, several 
investigators (1,4) have presented data consistent with tol- 
erance to organic nitrates using treadmill exercise testing as 
an endpoint. However, the variability of the time on the 
treadmill decreases the reproducibility of the measurements. 
Table 3. Changes in Heart Rate and Mean Blood Pressure From the Rest State With Graded Doses 
of 50, 100 and 200 Intracoronary pg Nitroglycerin (mean + SD) 
Heart Rate Mean Blood Pressure 
50 c(g 100 I*g 200 CLg 50 CLg 100 I.Lg 200 pg 
Control (no patch) -124 group 0+6 -I kfl -4 + 5 -7 k 5 -II k 5 
5mgi24hpatch2to12h 124 3k5 5tx -5 k 9 -8 ? IO -I??9 
before art. ~Group 1) 
I5 mgi24 h patch 2 to 12 h 024 o-+4 Ii-4 -2 -’ 3 -4 t 5 -7 + 5 
before art. ~Group 2) 
5 mgi24 h patch 24 h 3+3 426 62X -3 ? 2 -9 f 5 -IS?6 
before art. (Group 3) 
15 mgi24 h patch 24 h -2 t 5 I?5 057 ~6 t 5 -6 + 5 -8 + 5 
before art. t Group 4) 
art. = coronary arteriography; NTG = nitroglycerin. 
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Figure 3. Hypothesis of development of tolerance to nitroglycerin 
as measured by coronary artery dilative response to intracoronary 
nitroglycerin (NTG). The vertical axis represents percent dilation of 
the epicardial coronary artery (increase in coronary artery diameter) 
induced by nitroglycerin. A constant nitroglycerin blood level 
caused by the patch is assumed (“nitroglycerin level”). The hori- 
zontal axis represents time (in hours). After application of the patch 
(zero time), the coronary arteries dilate. With the passage of time, 
nitroglycerin tolerance develops and this dilative effect decays (thick 
line) despite constant nitroglycerin blood levels. High dose intraco- 
ronary nitroglycerin brings the dilation to 100% of possible nitro- 
glycerin-induced dilation (top horizontal line) causing a small addi- 
tional dilation early after the application of the patch (arrow a) and 
greater dilation 24 h after the patch (arrow b). 
In addition, one study (14) suggested that tolerance to 
nitrates is more pronounced or occurs only in the arterial 
system rather than the venous system. Because the effects of 
nitrates in patients with coronary artery disease occur at 
several sites including the coronary arteries, we have inves- 
tigated the occurrence of tolerance to organic nitrates by 
direct measurement of coronary artery diameter as visual- 
ized by coronary arteriography. 
Intracoronary nitroglycerin to assess tolerance to trans- 
dermal nitroglycerin patches. Our method is based on mea- 
suring the dose-dependent dilation of epicardial branches of 
the coronary arteries after incremental doses of intracoro- 
nary nitroglycerin. Our conclusions are based on the as- 
sumption that the powerful dilative response evoked by 
intracoronary nitroglycerin is manifested even in the pres- 
ence of tolerance. There is circumstantial evidence that this 
may be true, because in patients with angina pectoris sub- 
lingual nitroglycerin has been shown to overcome tolerance 
(17). We found that when a nitroglycerin patch was admin- 
istered a few hours before the test it caused significant 
coronary artery dilation and that the incremental dilation due 
to the intracoronary nitroglycerin was small (Fig. 3). On the 
other hand, 24 h after administration of intracoronary nitro- 
glycerin the coronary dilative effect of the patch was atten- 
uated because tolerance and the increment in diameter 
induced by intracoronary nitroglycerin was much larger 
(implying that the effect of the transdermal patch was 
smaller). Feldman et al. (7) showed that percent dilation is 
less in large coronary arteries than in smaller vessels. One 
may argue that in our study the groups with less dilation 
were the ones with larger baseline diameter. However, 
within this diameter range the reported dilation is 15 to 20%. 
Moreover, an average percent dilation of 5 to 9% after 
intracoronary nitroglycerin has been reported only for cor- 
onary segments with an average diameter of ~3.13 mm (8). 
In this study, in the group with the largest baseline diameter 
(Group 2, circumflex artery mean diameter 3.05 mm) the 
percent dilation was only 1 to 3%, a value much lower than 
would be expected. We believe that the larger arterial 
diameters observed in Groups 1 and 2 at baseline probably 
reflect a dilative effect by nitroglycerin patches administered 
a few hours before arteriography. 
Our results may be explained by the following alternative 
theories: 1) The patches may not deliver constant nitroglyc- 
erin blood levels for 24 h. This does not appear to be the 
case, as repeated trials of these patches have demonstrated 
constant blood levels throughout the day (l&19). 2) The 
effect of intracoronary nitroglycerin may be blunted early 
after administration of the patch or accentuated 24 h later. 
This “reverse tolerance” does not appear likely. 
Limitations of study. We believe that the data demon- 
strate tolerance. In any case, they demonstrate that the 
response to intracoronary nitroglycerin is altered by the 24 h 
patch. A limitation of this study is that nitroglycerin blood 
levels were not actually measured. As mentioned before, 
blood level data showed that patches release nitroglycerin at 
a constant rate. On the basis of this premise, studies of 
antianginal effects (I ,4) suggested development of tolerance 
within 24 h of the application of cutaneous nitroglycerin 
patches. Rose et al. (20) reported absence of differential 
effect of intracoronary nitroglycerin on coronary artery 
diameter in patients who had received it intravenously. It is 
difficult to explain the discrepancy. Our study was done in a 
blinded fashion and all data were analyzed without knowl- 
edge of treatment and group assignment, and those of 
intracoronary or patch by a single observer. 
Change in heart rate and mean blood pressure. Similarly 
to Feldman et al. (9), we observed that with the smallest 
dose of intracoronary nitroglycerin a significant (near maxi- 
mal) dilation of coronary arteries in the control group and 
minimal change in blood pressure and heart rate were 
present. At a maximal cumulative dose (350 pg nitroglyc- 
erin) there was a slight decrease in mean arterial pressure 
(range of means from 7 to 15 mm Hg) with only minimal 
changes in heart rate. There was no difference in the 
systemic response between untreated patients and those 
who had received a nitroglycerin patch. This lack of hemo- 
dynamic attenuation perhaps can be explained by attenua- 
tion of the arterial (including coronary) dilative effect being 
more prominent than attenuation of the venodilating effect 
(14). 
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